CN118436777A - 通过转换疗法治疗rms - Google Patents
通过转换疗法治疗rms Download PDFInfo
- Publication number
- CN118436777A CN118436777A CN202410529206.7A CN202410529206A CN118436777A CN 118436777 A CN118436777 A CN 118436777A CN 202410529206 A CN202410529206 A CN 202410529206A CN 118436777 A CN118436777 A CN 118436777A
- Authority
- CN
- China
- Prior art keywords
- ofatuzumab
- disease
- treatment
- dmt
- ofatumumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19196789.2 | 2019-09-11 | ||
| EP19196789 | 2019-09-11 | ||
| EP20154736.1 | 2020-01-30 | ||
| EP20154736 | 2020-01-30 | ||
| CN202080064158.9A CN114401742B (zh) | 2019-09-11 | 2020-09-10 | 通过转换疗法治疗rms |
| PCT/EP2020/075332 WO2021048280A1 (en) | 2019-09-11 | 2020-09-10 | Treatment of rms by switching therapy |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080064158.9A Division CN114401742B (zh) | 2019-09-11 | 2020-09-10 | 通过转换疗法治疗rms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118436777A true CN118436777A (zh) | 2024-08-06 |
Family
ID=72709332
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410529206.7A Pending CN118436777A (zh) | 2019-09-11 | 2020-09-10 | 通过转换疗法治疗rms |
| CN202080064158.9A Active CN114401742B (zh) | 2019-09-11 | 2020-09-10 | 通过转换疗法治疗rms |
| CN202410529209.0A Pending CN118403156A (zh) | 2019-09-11 | 2020-09-10 | 通过转换疗法治疗rms |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080064158.9A Active CN114401742B (zh) | 2019-09-11 | 2020-09-10 | 通过转换疗法治疗rms |
| CN202410529209.0A Pending CN118403156A (zh) | 2019-09-11 | 2020-09-10 | 通过转换疗法治疗rms |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220298253A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3864053B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7794735B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220062025A (cg-RX-API-DMAC7.html) |
| CN (3) | CN118436777A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020344154A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3150947A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3864053T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2957112T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3864053T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290619A (cg-RX-API-DMAC7.html) |
| LT (1) | LT3864053T (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022003010A (cg-RX-API-DMAC7.html) |
| SI (1) | SI3864053T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021048280A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4252847A3 (en) | 2016-08-15 | 2023-11-15 | Novartis AG | Regimens and methods of treating multiple sclerosis using ofatumumab |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| WO2021204994A1 (en) * | 2020-04-09 | 2021-10-14 | Novartis Ag | Ofatumumab for treating ms while maintaining serum igg |
| CA3215371A1 (en) * | 2021-04-13 | 2022-10-20 | Shibeshih Mitiku BELACHEW | Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome |
| CN117529336A (zh) * | 2021-04-14 | 2024-02-06 | 诺华股份有限公司 | 用于治疗亚洲患者的多发性硬化症的奥法木单抗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| HK1231413A1 (zh) * | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
| EP4252847A3 (en) * | 2016-08-15 | 2023-11-15 | Novartis AG | Regimens and methods of treating multiple sclerosis using ofatumumab |
-
2020
- 2020-09-10 JP JP2022515966A patent/JP7794735B2/ja active Active
- 2020-09-10 US US17/753,632 patent/US20220298253A1/en active Pending
- 2020-09-10 LT LTEPPCT/EP2020/075332T patent/LT3864053T/lt unknown
- 2020-09-10 EP EP20785440.7A patent/EP3864053B1/en active Active
- 2020-09-10 ES ES20785440T patent/ES2957112T3/es active Active
- 2020-09-10 AU AU2020344154A patent/AU2020344154A1/en active Pending
- 2020-09-10 CN CN202410529206.7A patent/CN118436777A/zh active Pending
- 2020-09-10 CN CN202080064158.9A patent/CN114401742B/zh active Active
- 2020-09-10 CN CN202410529209.0A patent/CN118403156A/zh active Pending
- 2020-09-10 DK DK20785440.7T patent/DK3864053T3/da active
- 2020-09-10 FI FIEP20785440.7T patent/FI3864053T3/fi active
- 2020-09-10 CA CA3150947A patent/CA3150947A1/en active Pending
- 2020-09-10 SI SI202030263T patent/SI3864053T1/sl unknown
- 2020-09-10 EP EP23183390.6A patent/EP4230655A3/en active Pending
- 2020-09-10 KR KR1020227011366A patent/KR20220062025A/ko not_active Ceased
- 2020-09-10 WO PCT/EP2020/075332 patent/WO2021048280A1/en not_active Ceased
- 2020-09-10 MX MX2022003010A patent/MX2022003010A/es unknown
-
2022
- 2022-02-14 IL IL290619A patent/IL290619A/en unknown
-
2025
- 2025-09-25 JP JP2025159217A patent/JP2026016387A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020344154A1 (en) | 2022-04-07 |
| EP4230655A2 (en) | 2023-08-23 |
| CN114401742A (zh) | 2022-04-26 |
| CN118403156A (zh) | 2024-07-30 |
| EP3864053B1 (en) | 2023-07-05 |
| DK3864053T3 (da) | 2023-09-11 |
| JP2026016387A (ja) | 2026-02-03 |
| LT3864053T (lt) | 2023-09-11 |
| CN114401742B (zh) | 2024-05-24 |
| SI3864053T1 (sl) | 2023-12-29 |
| MX2022003010A (es) | 2022-06-02 |
| US20220298253A1 (en) | 2022-09-22 |
| IL290619A (en) | 2022-04-01 |
| CA3150947A1 (en) | 2021-03-18 |
| KR20220062025A (ko) | 2022-05-13 |
| EP4230655A3 (en) | 2023-11-01 |
| JP7794735B2 (ja) | 2026-01-06 |
| FI3864053T3 (fi) | 2023-09-13 |
| EP3864053A1 (en) | 2021-08-18 |
| WO2021048280A1 (en) | 2021-03-18 |
| JP2022548575A (ja) | 2022-11-21 |
| ES2957112T3 (es) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114401742B (zh) | 通过转换疗法治疗rms | |
| JP2024156984A (ja) | 難治性全身型重症筋無力症の処置のための方法 | |
| US20010016195A1 (en) | Cytokine antagonists for the treatment of localized disorders | |
| CN112153982A (zh) | 用于通过施用il-4r抑制剂治疗特应性皮炎的方法 | |
| WO2023144699A1 (en) | Methods for treatment of subjects with plaque psoriasis of the scalp | |
| CA3229704A1 (en) | Ofatumumab for treating pediatric ms | |
| JP2026009900A (ja) | 血清IgGを維持しながらMSを治療するためのオファツムマブ | |
| RU2849464C1 (ru) | Лечение rms путем смены терапии | |
| HK40051003B (en) | Treatment of rms by switching therapy | |
| HK40051003A (en) | Treatment of rms by switching therapy | |
| Ryan et al. | Providing pharmaceutical care to the multiple sclerosis patient | |
| CN117813328A (zh) | 用于治疗儿童ms的奥法妥木单抗 | |
| Saeidi et al. | Observational Study on the Safety and Efficacy of Rituximab in Multiple Sclerosis: Insights from North-Eastern Iran: Rituximab Efficacy and Safety in MS: Iran | |
| TW202300523A (zh) | 用於治療MS同時維持血清IgG之奧法木單抗(OFATUMUMAB) | |
| BR122024017958A2 (pt) | Usos de ofatumumab para tratamento de esclerose múltipla (em) enquanto mantém a igg sérica | |
| Bašić Kes et al. | Preporuke za dijagnostiku i liječenje multiple skleroze |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |